← HALOZYME THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $146.7m |
$316.6m
+115.84%
|
$151.9m
-52.04%
|
$196.0m
+29.06%
|
$267.6m
+36.53%
|
$443.3m
+65.67%
|
$660.1m
+48.91%
|
$829.3m
+25.62%
|
$1.0b
+22.44%
|
$1.4b
+37.55%
|
$1.7b
+19.13%
|
|
| Cost of Revenue | $33.2m |
$31.2m
-6.19%
|
$10.1m
-67.46%
|
$45.5m
+349.35%
|
$43.4m
-4.78%
|
$81.4m
+87.73%
|
$139.3m
+71.11%
|
$192.4m
+38.09%
|
$159.4m
-17.13%
|
$228.8m
+43.51%
|
$292.4m
+27.82%
|
|
| Gross Profit (Calculated) | $113.5m |
$285.5m
+151.54%
|
$141.7m
-50.35%
|
$150.4m
+6.15%
|
$224.2m
+49.04%
|
$361.9m
+61.40%
|
$520.8m
+43.91%
|
$636.9m
+22.29%
|
$855.9m
+34.39%
|
$1.2b
+36.44%
|
— | |
| Research and Development Expense | $150.8m | $150.6m | $150.3m | $140.8m | $34.2m | $35.7m | $66.6m | $76.4m | $79.0m | $284.9m | $102.4m | |
| Selling, General and Administrative Expense | $45.9m | $53.8m | $60.8m | $77.3m | $45.7m | $50.3m | $143.5m | $149.2m | $154.3m | $207.1m | $238.0m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $43.1m | $73.8m | $71.0m | $76.7m | — | |
| Operating Lease, Expense | — | — | — | — | — | $2.0m | $3.3m | $9.3m | $8.6m | $9.4m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($83.2m) |
$81.0m
+197.35%
|
($69.3m)
-185.59%
|
($67.6m)
+2.48%
|
$144.3m
+313.36%
|
$275.9m
+91.26%
|
$267.5m
-3.03%
|
$337.6m
+26.18%
|
$551.5m
+63.36%
|
$469.0m
-14.95%
|
$930.8m
+98.46%
|
|
| Interest Expense, Debt | $20.0m | — | — | — | $19.9m | — | — | — | — | — | $20.3m | |
| Investment Income, Net | $1.3m | — | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | — | $2.6m | $7.6m | $7.0m | $5.4m | $1.1m | $1.0m | $16.3m | $23.8m | $21.5m | — | |
| Interest Expense (non-operating) | $20.0m | $22.0m | $18.0m | $11.6m | $20.4m | $7.5m | $16.9m | $18.8m | $18.1m | $18.1m | $20.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $6.4m | $160.9m | ($45.8m) | ($70.7m) | $130.4m | $248.1m | $248.9m | $348.8m | $557.9m | $467.5m | $583.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($101.9m) | $61.6m | ($79.8m) | ($72.3m) | $129.3m | $248.5m | $248.9m | $348.3m | $557.1m | $466.9m | $583.3m | |
| Income Tax Expense (Benefit) | $1.2m | ($1.4m) | $537k | ($11k) | $217k | ($154.2m) | $46.8m | $66.7m | $113.0m | $150.0m | $169.7m | |
| Net Income (Loss) Attributable to Parent | ($103.0m) |
$63.0m
+161.12%
|
($80.3m)
-227.57%
|
($72.2m)
+10.07%
|
$129.1m
+278.69%
|
$402.7m
+211.97%
|
$202.1m
-49.81%
|
$281.6m
+39.31%
|
$444.1m
+57.71%
|
$316.9m
-28.64%
|
$413.6m
+30.52%
|
|
| Earnings Per Share, Basic | ($0.81) | $0.46 | ($0.56) | — | $0.95 | $2.86 | $1.48 | $2.13 | $3.50 | $2.64 | $3.55 | |
| Earnings Per Share, Diluted | ($0.81) | $0.45 | ($0.56) | ($0.50) | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 | $3.41 | |
| Weighted Average Number of Shares Outstanding, Basic | — | 136.4m | 143.6m | 144.3m | 136.2m | 140.6m | 136.8m | 131.9m | 126.8m | 119.8m | 117.6m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 139.1m | 143.6m | 144.3m | 141.5m | 146.8m | 140.6m | 134.2m | 129.4m | 123.9m | 122.2m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $229.9m | $235.6m | $221.2m | $263.6m | $123.3m | $167.4m | $392.6m | $491.7m | $463.8m | $927.6m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.